Navigation Links
Exosome Diagnostics Appoints Johan Skog, Ph.D., as Director of Genetics Research
Date:9/12/2008

NEW YORK, Sept. 12 /PRNewswire/ -- Exosome Diagnostics, Inc. today announced the appointment of Johan Skog, Ph.D., as director of genetics research. In this role, Dr. Skog will oversee the research program that underlies the company's development of its blood-based diagnostics that can identify cancer-specific genetic mutations.

Dr. Skog is the primary discoverer and inventor of Exosome Diagnostics' core technology that has been licensed exclusively to the company by Massachusetts General Hospital. He is also a post-doctoral researcher at the molecular neurogenetics unit of Massachusetts General Hospital. Dr. Skog received his Ph.D. specializing in gene therapy from Umea University in Sweden.

"Dr. Skog's discoveries are the foundation of our development program to capture diagnostic quantities of genetic mutations in blood," said James McCullough, chairman & chief executive officer. "His expertise as the inventor of the technology of isolating genetic mutations from circulating exosomes for use as diagnostic and prognostic tools will enable the company to rapidly move forward on its first program, a blood-based diagnostic for brain cancer."

About Exosome Diagnostics

Exosome Diagnostics is a developer of proprietary genetics-based diagnostic tests with applications in oncology and endocrinology. Exosome's core technology is based on the discovery that circulating nanovesicles called exosomes contain unique genetic markers and that they can be reliably harvested and used as a diagnostic tool for cancers and metabolic diseases. Exosome Diagnostics' lead program is a blood-based diagnostic test for the management of brain cancer patients. For more information, visit http://www.exosomedx.com.


'/>"/>
SOURCE Exosome Diagnostics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Exosome Diagnostics Announces Additions to Management Team
2. Boveran Diagnostics, Inc. Announces Planned Acquisition of New York-Based Pathology Lab: Sophora Diagnostic Lab, Inc.
3. Pathwork Diagnostics Closes $20M Financing
4. VentriPoint Diagnostics Files Management Discussion and Analysis, Unaudited Financial Results for 2Q 2008
5. Biotest Diagnostics Receives FDA Clearance for Full Line of Traditional Blood Bank Reagents
6. Dr. George Poste Named Non-Executive Vice Chairman of CDX Holdings, Parent of Caris Diagnostics and Caris Molecular Diagnostics
7. DeviceSpace(TM) to Host Medical Device and Diagnostics Career Fair in Minneapolis
8. Quest Diagnostics to Release Second Quarter 2008 Financial Results
9. VTT Technical Research Centre of Finland Licenses MetaCore from GeneGo for Cancer Research and Diagnostics
10. Premier Healthcare Alliance Honors Siemens Healthcare Diagnostics for Excellence in Supplier Performance
11. HemoCue Receives First FDA CLIA Waiver in Diagnostics Industry for Quantitative Point-of-Care Test for Microalbuminuria, a Kidney and Cardiovascular Disease Risk Marker
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... January 20, 2017 Stock-Callers.com explores ... have influenced the most recent performances of select equities. ... RGLS ), Abeona Therapeutics Inc. (NASDAQ: ... TBPH ), and Sage Therapeutics Inc. (NASDAQ: ... Grand View Research, global Biotech market size is expected to reach $604.40 ...
(Date:1/19/2017)... , Jan 19, 2017 Research and ... by Profiling Technology, Biomolecules, Cancer Type, Application - Global Opportunity Analysis ... ... forecasts that the global market is projected to reach $15,737 million ... 13% from 2016 to 2022. Omic technologies segment ...
(Date:1/19/2017)... -- Research and Markets ... has announced the addition of the "Implantable ... report to their offering. Report Highlights: ... a detailed analysis on current and future market trends to identify the ... values as the base numbers Key market trends across ...
(Date:1/19/2017)... 2017  ArmaGen, Inc., today announced that it ... chief executive officer, as well as a member ... ArmaGen more than 17 years of executive management ... biotherapeutics and pharmaceuticals. "Mathias is ... and skillset necessary to lead ArmaGen to its ...
Breaking Biology Technology:
(Date:1/18/2017)... 18, 2017 MedNet Solutions , ... the entire spectrum of clinical research, is proud ... year for the organization in terms of corporate ... eClinical products and services. The company,s exceptional achievements ... of iMedNet ™ ...
(Date:1/12/2017)... -- Trovagene, Inc. (NASDAQ: TROV ), a developer ... it has signed agreements with seven strategic partners across ... Middle East for commercialization of the Trovera™ ... of international distribution agreements for Trovagene,s CLIA based liquid ... The initial partners will introduce Trovagene,s liquid biopsy tests ...
(Date:1/12/2017)... , January 12, 2017 A new report by Allied Market ... the global biometric technology market is expected to generate revenue of $10.72 billion by ... Continue Reading ... Allied Market Research Logo ...      (Logo: http://photos.prnewswire.com/prnh/20140911/647229) ...
Breaking Biology News(10 mins):